- ENTA has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $16.1 million.
- ENTA has traded 10,105 shares today.
- ENTA is trading at a new lifetime high.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in ENTA with the Ticky from Trade-Ideas. See the FREE profile for ENTA NOW at Trade-Ideas More details on ENTA: Enanta Pharmaceuticals, Inc., a biotechnology company, is engaged in the development of small molecule drugs for the infectious disease field. ENTA has a PE ratio of 25.1. Currently there are 2 analysts that rate Enanta Pharmaceuticals a buy, no analysts rate it a sell, and 2 rate it a hold. The average volume for Enanta Pharmaceuticals has been 305,800 shares per day over the past 30 days. Enanta has a market cap of $840.1 million and is part of the health care sector and drugs industry. Shares are up 66.2% year-to-date as of the close of trading on Tuesday. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. TheStreetRatings.com Analysis: TheStreet Quant Ratings rates Enanta Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its notable return on equity, robust revenue growth and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we find that the growth in the company's net income has been quite unimpressive.